23 Jul, 2026
The global osteoarthritis treatment market size reached USD 7.69 billion in 2025 and is anticipated to grow from USD 8.05 billion in 2026 to USD 11.66 billion by 2034, expanding at a CAGR of 4.74% over the forecast period from 2026 to 2034.
Degenerative arthritis, also known as osteoarthritis, is the most prevalent chronic condition affecting the joints. Acute joint pain and stiffness are consequently felt in the affected body parts. Painkillers and exercises that reduce joint pain are two ways osteoarthritis can be treated. Painkillers available over-the-counter (OTC) that can help with OA symptoms include acetaminophen (Tylenol) and nonsteroidal anti-inflammatory drugs (NSAIDs) (NSAID). The painkiller duloxetine (Cymbalta), used to manage chronic (long-term) OA discomfort, can be used to treat it. Steroid injections can often significantly reduce OA pain in short- to medium-term.
Osteoarthritis is a widespread, multifactorial joint disease affecting millions worldwide. It progresses over time and is characterized by functional impairment and chronic pain. Knee osteoarthritis accounts for nearly half of the burden of osteoarthritis globally, and it worsens with age and obesity, according to a study by Aiyong Cui et al. published in the December 2020 issue of the Lancet Journal. Osteoarthritis is more common in women, and some risk factors for a high incidence of the condition include being overweight, getting older, being obese, sustaining a knee injury, having weak muscles, having low bone density, and having loose joints. As a result, it is anticipated that demand for therapeutics will rise during the forecast period as osteoarthritis incidence increases globally.
Due to rising rates of obesity and extended life expectancy, osteoarthritis (OA) has become the most prevalent rheumatic condition worldwide. The functional capacity of people with osteoarthritis is severely reduced, making it one of the major causes of disability. Several therapy options and mechanisms are based on mechanical, inflammatory, and metabolic aspects. By focusing on synovitis brought on by the NOD-like receptor protein 3 (NLRP3) inflammasome, research and development efforts have been made to assess the pain-relieving potential of vanillic acid (VA). Additionally, it was found that knee osteoarthritis (KOA) pain is significantly influenced by synovitis. The market is expected to expand due to the high prevalence of osteoarthritis and increasing research and development efforts to develop new potent therapeutics.
North America is the most significant shareholder in the global osteoarthritis treatment market and is expected to grow at a CAGR of 5.82% during the forecast period. The major drivers of the US market expansion are technological development, rising geriatric and obese populations, and diseases related to the knee, like osteoarthritis, that are becoming more common. Osteoarthritis (OA), the most prevalent type of arthritis and a severe chronic condition affecting 1 in 7 adults in the United States, affected 32.5 million people in 2020, according to the National Public Health Agenda for Osteoarthritis 2020 Update by the Osteoarthritis Action Alliance. The market is also anticipated to benefit from the growing research and development efforts in the United States to develop novel therapeutics.
Asia-Pacific is expected to grow at a CAGR of 6.28%, generating USD 2,630.84 million during the forecast period. Rising osteoarthritis prevalence, key market players, and Japan's growing geriatric population are expected to expand the Japanese market for osteoarthritis treatment. Osteoarthritis is the most common joint condition and the leading cause of disability in Japan's elderly. In Japan, patients with knee osteoarthritis and osteoarthritis at another site (KOA/+) received more pain-related care than those with knee osteoarthritis alone (KOA/O). People in the country choose pain-related treatments for osteoarthritis, which boosts the market. Major market players prioritize product launches, developments, and partnerships with local market players and regional government organizations to develop novel medicines. These factors should increase the demand for osteoarthritis treatments in Japan.
The aging of the European population, a risk factor for osteoarthritis, and rising osteoarthritis incidence in Germany are driving the market growth. According to the World Population Ageing Report 2019, 18.009 million Germans are 65 or older. This number could reach 21.767 million by 2030. The prevalence of osteoarthritis is expected to rise in Germany over the next few years as the population ages. In October 2020, Novartis acquired the Phase II study-involved investigational drug M6495 from Merck KGaA. Anti-ADAMTS5 Nanobody is injected subcutaneously to maintain knee joint integrity and reduce OA pain. These factors will remain throughout the forecast period, which is anticipated to drive market growth.
sales@straitsresearch.com